Posted: December 17, 2021
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism. David L. McGlasson, MS, MLS(ASCP) INTRODUCTION Thromboembolism is a leading cause of mortality and morbidity. Treatment with anticoagulants is prescribed, but balancing bleeding and clotting has been a challenge. In the 1940s, unfractionated heparin (UFH) became available for use by intravenous or…
Posted: September 27, 2021
A Trio of Biomarkers: A Novel Multivariate Model to Detect DILI & Liver Damage -Contributed by Abi Kasberg, PhD While maybe underappreciated, Drug-induced liver injury (DILI) is a condition with significant impact on the medical world. DILI is the leading cause of acute liver failure and is frequently responsible for the termination and withdrawal of…
Posted: September 27, 2021
Clot Club – ISTH 2021 David L. McGlasson, MS, MLS(ASCP) Attending the International Society of Thrombosis and Hemostasis 2021 virtually from July 17-21, 2021 was quite a challenge this year. There were lots of information ranging from clinical, to what I would call “futuristic” research, that we might not see put into clinical practice for…
Posted: August 19, 2021
Thrombotic Thrombocytopenic Purpura (TTP) Clinical Trials: Targeting the needs left by current treatment options -Contributed by Abi Kasberg, PhD Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy blood disorder that is characterized by the formation of blood clots in small blood vessels, thrombocytopenia, and a lack of ADAMTS-13 (a disintegrin-like and metalloproteinase with thrombospondin…